Fredun Pharmaceuticals Reports Strong Q2 FY24-25 Growth Amid Market Challenges
Fredun Pharmaceuticals has recently adjusted its evaluation, highlighting its financial performance in the pharmaceuticals sector. The company reported significant growth in net sales and operating profit for Q2 FY24-25, with notable increases in profit after tax and operational efficiency, despite a challenging year.
Fredun Pharmaceuticals has recently undergone an evaluation adjustment, reflecting a nuanced perspective on its financial standing within the pharmaceuticals and drugs industry. The company, categorized as a microcap, has demonstrated notable growth metrics in its latest quarterly performance for Q2 FY24-25. Specifically, net sales have expanded at an annual rate of 26.87%, while operating profit has shown a growth rate of 31.05%. In the most recent results for September 2024, the profit after tax (PAT) reached Rs 8.40 crore, marking a growth of 32.49%. Additionally, net sales for the quarter stood at Rs 107.35 crore, with a growth rate of 30.95%. The company also reported its highest PBDIT at Rs 13.94 crore, indicating strong operational efficiency.
With a return on capital employed (ROCE) of 12.3 and an enterprise value to capital employed ratio of 2, Fredun Pharmaceuticals presents an attractive valuation. Despite a return of -11.26% over the past year, the company's profits have increased by 29.2%, and its PEG ratio is noted at 0.7.
The stock's technical indicators suggest a mildly bearish trend, and it has consistently underperformed against the benchmark over the last three years.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
